Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

7.4K
Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
7.4K
Synthesis and Regulation of Thyroid Hormones01:20

Synthesis and Regulation of Thyroid Hormones

8.3K
Low blood levels of the thyroid hormones — triiodothyronine (T3) and thyroxine (T4) — signal the hypothalamus to release the thyrotropin-releasing hormone (TRH). TRH then reaches the pituitary gland and stimulates the release of thyroid-stimulating hormone(TSH) into the bloodstream.
Upon reaching the thyroid gland, TSH stimulates the follicular cells' active uptake of iodide ions from the blood. The ions diffuse to the apical surface of the cells and are oxidized to iodine. The...
8.3K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

4.9K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
4.9K
Amplifying Signals via Enzymatic Cascade01:22

Amplifying Signals via Enzymatic Cascade

18.7K
When a ligand binds to a cell-surface receptor, the receptor's intracellular domain changes shape, which may either activate its enzyme function or allow its binding to other molecules. The initial signal is amplified by most signal transduction pathways. This means that a single ligand molecule can activate multiple molecules of a downstream target. Proteins that relay a signal are most commonly phosphorylated at one or more sites, activating or inactivating the protein. Kinases catalyze...
18.7K
MAPK Signaling Cascades01:07

MAPK Signaling Cascades

8.8K
Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
8.8K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

5.8K
The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
5.8K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Expanding Bevacizumab-Erlotinib Therapy Through Fumarate Hydratase Deficiency Screening and Drug Target Pathway Analysis in Papillary Morphology Metastatic Renal Cell Carcinoma.

European urology·2026
Same author

Targeted radioiodine therapy of ovarian cancer via the sodium/iodide symporter (NIS).

Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie·2025
Same author

A Novel Missense Variant in the NKX2-1 <i>Homeodomain</i> Prevents Transcriptional Rescue by TAZ.

Thyroid : official journal of the American Thyroid Association·2024
Same author

Focal adhesion kinase-YAP signaling axis drives drug-tolerant persister cells and residual disease in lung cancer.

Nature communications·2024
Same author

GLIS3 regulates transcription of thyroid hormone biosynthetic genes in coordination with other thyroid transcription factors.

Cell & bioscience·2023
Same author

Inhibiting ERK dimerization ameliorates BRAF-driven anaplastic thyroid cancer.

Cellular and molecular life sciences : CMLS·2022

Related Experiment Video

Updated: Feb 24, 2026

Induction and Analysis of Epithelial to Mesenchymal Transition
10:37

Induction and Analysis of Epithelial to Mesenchymal Transition

Published on: August 27, 2013

36.6K

Key signaling pathways in thyroid cancer.

Miguel A Zaballos1, Pilar Santisteban2

  • 1Instituto de Investigaciones Biomédicas 'Alberto Sols'Consejo Superior de Investigaciones Científicas (CSIC), Universidad Autónoma de Madrid (UAM), Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Instituto de Salud Carlos III (ISCIII), Madrid, Spain.

The Journal of Endocrinology
|August 26, 2017
PubMed
Summary
This summary is machine-generated.

Whole genome sequencing reveals MAPK and PI3K pathways are key in thyroid cancer. While targeted therapies show promise, drug resistance remains a significant challenge for patient treatment.

Keywords:
MAPKPI3Kcancersignalingthyroid

More Related Videos

In Vivo Inhibition of MicroRNA to Decrease Tumor Growth in Mice
07:02

In Vivo Inhibition of MicroRNA to Decrease Tumor Growth in Mice

Published on: August 23, 2019

7.8K
Spontaneous Murine Model of Anaplastic Thyroid Cancer
05:39

Spontaneous Murine Model of Anaplastic Thyroid Cancer

Published on: February 3, 2023

2.3K

Related Experiment Videos

Last Updated: Feb 24, 2026

Induction and Analysis of Epithelial to Mesenchymal Transition
10:37

Induction and Analysis of Epithelial to Mesenchymal Transition

Published on: August 27, 2013

36.6K
In Vivo Inhibition of MicroRNA to Decrease Tumor Growth in Mice
07:02

In Vivo Inhibition of MicroRNA to Decrease Tumor Growth in Mice

Published on: August 23, 2019

7.8K
Spontaneous Murine Model of Anaplastic Thyroid Cancer
05:39

Spontaneous Murine Model of Anaplastic Thyroid Cancer

Published on: February 3, 2023

2.3K

Area of Science:

  • Oncology
  • Genetics
  • Molecular Biology

Background:

  • Thyroid carcinomas are driven by genetic lesions affecting key signaling pathways.
  • The MAPK (mitogen-activated protein kinase) and PI3K (phosphatidylinositol-4,5-bisphosphate 3-kinase) signaling cascades are central to thyroid tumorigenesis.
  • These pathways are complex, involving numerous components and interactions.

Purpose of the Study:

  • To review the latest findings on MAPK and PI3K pathways in thyroid cancer.
  • To discuss their activation mechanisms, genetic alterations, and therapeutic targeting.
  • To highlight challenges such as drug resistance.

Main Methods:

  • Review of whole genome sequencing data.
  • Analysis of genetic alterations in thyroid carcinomas.
  • Discussion of small-molecule inhibitors and clinical trial outcomes.

Main Results:

  • Whole genome sequencing has identified critical genetic lesions in thyroid cancer.
  • MAPK and PI3K pathways are consistently activated in thyroid tumorigenesis.
  • Targeted inhibitors show therapeutic potential but face resistance issues.

Conclusions:

  • Understanding MAPK and PI3K pathways is crucial for thyroid cancer treatment.
  • Development of novel therapeutics targeting these pathways is ongoing.
  • Addressing drug resistance mechanisms is essential to improve patient outcomes.